Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
IPO Year:
Exchange: NASDAQ
Website: profoundmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/23/2024 | $16.50 | Buy | Lake Street |
| 7/16/2024 | $9.00 → $12.00 | Hold → Buy | Stifel |
| 11/28/2023 | $11.00 | Hold | Stifel |
| 8/4/2023 | $20.00 → $200.00 | Strong Buy → Outperform | Raymond James |
| 3/21/2023 | $5.50 → $10.00 | Buy → Hold | Jefferies |
| 3/7/2022 | $28.00 → $14.00 | Outperform | Cowen & Co. |
| 2/22/2022 | $28.00 → $23.00 | Strong Buy → Outperform | Raymond James |
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its hybrid (in-person and virtual) investor event taking place on Monday, April 28, 2025, during the American Urological Association's ("AUA") Annual Meeting. The event will be held at the Waldorf Astoria in Las Vegas, NV. The agenda will commence at 3:30 p.m. Pacific Time (6:30 p.m. Eastern Time) and is scheduled to conclude at approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern T
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association's ("AUA") Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m. Eastern Time). "The program will feature presentations from members of Profound's management team as well as by leading physicians on: (1) TULSA-PRO® and its unrivalled flexibility to treat a wide
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2024 Results Conference Call Details: Date: Thursday, March 6, 2025 Time: 4:30 p.m. ET Live Call Registration: https://
TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its scheduled presentation time at the 43rd Annual J.P. Morgan Healthcare Conference has been changed to 9:00 a.m. Pacific Time on Thursday, January 16, 2025. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. About Profound Medical Corp. Profound is a commercial-stage medical device company that deve
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2024. Profound anticipates total revenue for the fourth q
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 11:15 a.m. Pacific Time in San Francisco, CA. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section. About Profound Medical Corp. Profound is a commercial-stage medical dev
TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of common shares (the "Common Shares") at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares being issued today for aggregate gross proceeds, before deducting the underwriting discounts and commissions and other offering expenses payable by Profound, of approximately US$40.25 million. The net proceeds of the Offering are expected to be used: (i) t
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") today announced the pricing of an underwritten public offering (the "Offering") of 4,666,700 common shares (the "Common Shares") at a public offering price of US$7.50 per Common Share. The gross proceeds of the Offering to Profound, before deducting the underwriting discounts and commissions and other offering expenses payable by Profound, are expected to be approximately US$35 million. In addition, Profound has granted the underwriters
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2025 Results Conference Call Details: Date: Thursday, May 8, 2025 Time: 4:30 p.m. ET Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the fourth quarter and full year ended December 31, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP). Business Highlights Q4-2024 revenue growth of 108% over Q4-2023.During the fourth quarter, Profound made two key executive changes to fur
TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2024 Results Conference Call Details: Date: Thursday, March 6, 2025 Time: 4:30 p.m. ET Live Call Registration: https://
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights Q3-2024 revenue growth of 64% over Q3-2023.Profound continued to see a wide variety of prostate dise
TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Third Quarter 2024 Results Conference Call Details: Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI0b43a811a8b6
TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2024. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed base grew from 53 at the end of Q1-2024 to 57 as of the end of Q2-2024;
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2024 financial results after market close on Thursday, August 8, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Second Quarter 2024 Results Conference Call Details: Date: Thursday, August 8, 2024 Time: 4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BIbfa8c9bee6c646
TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Business Highlights The TULSA-PRO® systems installed
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. First Quarter 2024 Results Conference Call Details: Date:Thursday, May 9, 2024Time:4:30 p.m. ET Live Call Registration: https://register.vevent.com/register/BI477e53fa85fe419682e13b58f273
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Fourth Quarter and Full Year 2023 Results Conference Call Details:Date:Thursday, March 7, 2024Time:4:30 p.m. ETLive Call Registration:https://register.vevent.com/register/B
Lake Street initiated coverage of Profound Medical with a rating of Buy and set a new price target of $16.50
Stifel upgraded Profound Medical from Hold to Buy and set a new price target of $12.00 from $9.00 previously
Stifel initiated coverage of Profound Medical with a rating of Hold and set a new price target of $11.00
Raymond James downgraded Profound Medical from Strong Buy to Outperform and set a new price target of $200.00 from $20.00 previously
Jefferies downgraded Profound Medical from Buy to Hold and set a new price target of $10.00 from $5.50 previously
Cowen & Co. reiterated coverage of Profound Medical with a rating of Outperform and set a new price target of $14.00 from $28.00 previously
Raymond James downgraded Profound Medical from Strong Buy to Outperform and set a new price target of $23.00 from $28.00 previously
Raymond James initiated coverage of Profound Medical with a rating of Strong-Buy and set a new price target of $34.00
Lake Street Capital reiterated coverage of Profound Medical with a rating of and set a new price target of $32.00 from $27.00 previously
– Mr. Tamberrino and Profound's CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of Tom Tamberrino as its new Chief Commercial Officer. Abbey Goodman, the Company's current CCO, will t
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Comp
TORONTO, May 15, 2024 /CNW/ - Profound Medical Corp. (TSX:PRN) (NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the "Meeting"). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 5, 2024 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all
TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 6, 2023 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the
TORONTO, May 18, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the "Meeting"). A total of 12,858,319 common shares, representing 61.880% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 8, 2022 (the "Information Circular"), were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the sharehol
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the appointment of accomplished global medical device industry veteran, Kenneth Knudson, as Chief Commercial Officer. Mr. Knudson's mandate will be leading Profound's worldwide sales, marketing and reimbursement activities. In an executive management career spanning more than 25 years, Mr. Knudson has achieved results ranging from accelerating growth for emerging start-ups to advancing success for Fortune 500 compa
TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN, NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the "Meeting"). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated April 9, 2021, were approved by the requisite majority of votes cast at the Meeting. Election of Directors At the meeting, the shareholders of the Company elected all seven nominees for th
HAMILTON, ON, April 29, 2021 /CNW/ - The Board of Directors for Insight Medbotics, a start-up founded by MDA and the Centre for Surgical Invention and Innovation (CSii), are pleased to announce the appointment of Paul Chipperton as the company's Chief Executive Officer & President. Mr. Chipperton will be responsible for ensuring the successful execution of existing projects, including the IGAR (Image Guided Automated Robot), the world's first Magnetic Resonance Imaging (MRI) guided breast cancer robot. Mr. Chipperton is a 25-year Medtech veteran, and has raised capital at al
TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors. A seasoned healthcare investment professional with 18 years of experience in venture capital, Dr. Lavoie’s expertise includes creating companies de novo and leading investments into businesses developing therapeutics, devices, and diagnostic tools. Dr. Lavoie is currently President and Managing Director of AllosteRx Capital Management (“AllosteRx”). She also
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
SC 13G/A - Profound Medical Corp. (0001628808) (Subject)
8-K - Profound Medical Corp. (0001628808) (Filer)
10-K - Profound Medical Corp. (0001628808) (Filer)
8-K - Profound Medical Corp. (0001628808) (Filer)
SCHEDULE 13G/A - Profound Medical Corp. (0001628808) (Subject)
8-K - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)
SUPPL - Profound Medical Corp. (0001628808) (Filer)
6-K - Profound Medical Corp. (0001628808) (Filer)